ARTTIC assists clients from all business and research sectors, small and large, private and public, to ensure the success of their collaborative research and innovation ventures. During close to 30 years of success, ARTTIC developed and demonstrated expertise in the set-up and management of more than 300 large-scale ambitious projects. Based on its long-standing experience in a range of funding programmes across scientific and technological domains, ARTTIC helps clients to move from strategic plans to effective competitive research and development of innovative solutions, resulting in successful applications and high-performance businesses.
Founded in Paris in 1987, ARTTIC is now a group of companies with main offices in France (Paris and Toulouse), Germany (Munich and Berlin), Belgium (Brussels), England (Derby) and Israel (Tel Aviv). In 2015, ARTTIC has been ranked first SME in Europe by the European Commission considering the number of grant agreements signed by ARTTIC.
Founded in 2013 as a subsidiary of BioCity, BioAscent provides a ‘centre of excellence’ for compound management activities within the EU Lead Factory. It is responsible for collection and storage of both solid and DMSO solutions, and it handles subsequent distribution of screening plates, as well as hit picking to support follow-up studies. BioAscent tracks the entire EU Lead Factory Joint European Compound Library (JECL).
BioAscent operates at the former Organon/Merck Sharp and Dohme research facilities at Newhouse Scotland. Clients appreciate access to leading compound management and logistics services, which are designed to ensure optimum value, accessibility and protection for their compound collections.
The storage technology employed maximises the lifespan and quality of compound solutions by providing the flexibility of random, rapid and individual selection of required samples only. BioAscent’s core focus is on ensuring simple and productive access to diverse new compound collections, either via their own BioAscent compound collections (BCCs), or through using the BioAscent storage and IT infrastructure that is designed to share securely the collections of others.
ChemAxon is a leading global cheminformatics company, which provides web-enabled software applications and toolkits for chemists and biologists, among others. This software enables structure visualization and management, property predictions and calculations, virtual synthesis, screening, clustering and drug design. Within the EU Lead Factory project, ChemAxon has been building a portal to support crowd-sourcing using its core JChem Base and Marvin components. Scientific decisions taken while selecting successful proposals are supported by ChemAxon’s Discovery Toolkit, including various fingerprints and physico-chemical property predictors. The portal also gives submitters a way to keep track of their submission’s status and for the consortium’s selection committee to score and analyze submitted proposals.
Founded in early 2005 by senior life-sciences managers with extensive drug discovery expertise, Edelris is a privately-owned research and services company. It offers innovative natural-product‐like collections of screening compounds (Keymical Collections™); 3D pharmacophoric‐rich “Smart Fragments”; proven Natural Product total synthesis and derivatization expertise; and efficient hit/lead optimization capabilities. The Keymical Collections™ and Smart Fragments are designed to interact highly favourably with biological systems, increasing the potential for viable hits. More than 50 original compound series from the Keymical Collections™ comprise 100‐1,000 molecules per family and represent a total of over 10,000 potential hits with an average purity of >95%. Edelris also has a collection of 1900 fragments for FBDD, enhanced with Smart Fragments. Its hit exploration/lead optimization service is supported by a chemoinformatics/molecular modelling platform. The company has worked on several complex NP targets originally obtained from fermentation, either by derivatization of the natural source or by multi‐step total synthesis from commercially available building blocks.
Project leader: Jean-Yves Ortholand, CEO
For more information visit www.edelris.com
Lead Discovery Center GmbH
The Lead Discovery Center (LDC) aims to accelerate the professional translation of excellent basic research into innovative therapies for diseases with high medical need. Early stage projects from academia are transformed into innovative pharmaceutical leads that reach initial proof-of-concept in animals, with a focus on small molecules. Fostering pre-competitive collaborations as well as exchange with industry LDC sustains a preferred partnership with the Max Planck Society and has established alliances with AstraZeneca, Bayer, Daiichi-Sankyo, Merck, and Qurient as well as leading academic drug discovery centers around the globe. Core expertise includes cellular biology, assay development & screening, pharmacology and medicinal chemistry. LDC brings its industry-standard cheminformatics and medicinal chemistry expertise to the EU Lead Factory for the design of the novel Public Compound Collection.
A privately-owned leading European contract research organization offering discovery chemistry, library chemistry, medicinal chemistry and early process research services including GMP synthesis to accelerate drug discovery and development. Mercachem was founded in 1997, occupies 4,500 m2 state-of-the-art research facilities in Nijmegen and employs around 140 chemists who work for many pharmaceutical and biotech companies throughout the world. The company has a proven track record in complex projects, balancing novel compound spaces, target spaces and advanced optimization paradigms. The library synthesis team consists of 15 dedicated chemists, who over the years have developed an optimized workflow for the design and efficient synthesis of libraries in a timely manner.
Pivot Park Screening Centre (PPSC)
Pivot Park Screening Centre provides services in the field of assay development, lab automation and High Throughput Screening (HTS) to find new leads for drug development. The screening facility includes state-of-the-art robotic facilities and an extensive collection of 225,000 high quality drug-like compounds. PPSC helps pharma, SME’s and academia to optimize their drug discovery process with more efficient processes and quick and accurate results. Established in 2012 as a spin-off from Organon/MSD, the Pivot Park Screening Centre uses a new, open approach to build on the long-established history of screening in Oss. The screening of compounds for the European Lead Factory takes place at the Pivot Park Screening Centre’s facilities in Oss, placing our facilities at the heart of EU Lead Factory. PPSC is part of Pivot Park, an inspiring campus for open innovation in the life sciences.
Project leader: Dr Steven van Helden
Want to get more details? Go to www.pivotparkscreeningcentre.com
Sygnature Discovery Ltd
Sygnature Discovery is the UK’s largest independent provider of integrated drug discovery resource for academic departments, pharmaceutical and biotechnology companies worldwide. Sygnature adds value to clients’ research by providing advanced scientific knowledge and expertise to accelerate hit identification, hit to lead and lead optimisation projects. In-house capabilities include medicinal chemistry, in vitro bioscience, computational chemistry, DMPK, physical sciences and informatics. Over 100 experienced and highly qualified laboratory based scientists utilize novel technologies and innovative ways of working to ensure successful delivery on the most complex of research programmes.
Syncom, is an independent CRO/SME in the North of the Netherlands with a proven 25-year track record in assisting leading pharma and biotechnology companies with medicinal chemistry programs. Clients include 15 out of the top 20 pharma companies. The firm has designed and synthesised numerous unique scaffolds, yielding many patent applications and clinical candidates. Syncom is one of the five SMEs contributing to synthesis of 200,000 compounds for the EU Lead Factory Public Compound Collection.
Taros Chemicals GmbH & Co. KG
Taros, an independent and privately owned contract research company based in Dortmund, Germany, has been serving the needs of pharmaceutical, chemical, agrochemical and biotech companies since 1999. Taros operates state-of-the art lab facilities and employs a team of scientists (65% of whom hold post-graduate degrees in Chemistry) who are committed to supporting the diverse needs of its customers in efficient drug discovery, medicinal chemistry and classical synthetic chemistry. Taros’ scientists combine more than 140 years industrial organic chemistry experience and over 60 years of active drug discovery experience from big pharmas and biotechs. They have expertise across a broad range of therapeutic areas (oncology, respiratory, CNS, cardiovascular, inflammation, pain, metabolism and infectious) and in all small molecule target classes. We have developed TarosGate®, a unique software suite putting cost, time and chemistry information at a Project Leader’s finger tips .